Delta-fly Pharma, Inc.

Taiho Pharmaceutical Company Limited

The University of Tokushima

Medrx Co., Ltd

Tokushima University

Nof Corporation

Tatsuhiro Ishida

Hiroshi Kikuchi

Kiyoshi Eshima

Hiromi Wada

Yusuke Doi

Hiroshi Kiwada

Masakazu Fukushima

Hidetoshi Hamamoto

Kazuhiro Kubo

Kenji Sakanoue

Yasushi Miwa

Cheng Long Huang

Reo Hamaguchi

Chika Ito

Cheng-Long Huang

The present invention provides a novel siRNA specifically inhibiting the expression of IL-23 and a pharmaceutical composition comprising the siRNA specifically a double stranded RNA comprising a sense strand and an antisense strand wherein each strand has 19 to 30 nucleotides and comprises the base sequence selected from SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5 or SEQ ID NO: 6 or a complementary base sequence thereof and a pharmaceutical composition comprising the double stranded RNA.

Double stranded RNA specifically inhibiting expression of IL-23 and pharmaceutical composition comprising same

An object of the present invention is to provide a new means for treating or ameliorating a blood cancer patient, wherein the new means has high effect and few side effects. The present invention relates to a combined medicine for use in a method for treating or ameliorating a blood cancer patient, comprising 4-amino-1-(2-cyano-2-deoxy-β-D-arabinofuranosyl)-2(1H)-pyrimidinone or a salt thereof and venetoclax or a salt thereof.

Therapy and new therapeutic agent for blood cancer

An object of the present invention is to provide a highly effective method for treatment/remission of cancer, and prevention of recurrence/metastasis of cancer at low cost and with few side effects. A composition containing a urinary alkalinization agent, for use in treatment or remission of cancer, or prevention of recurrence or metastasis of cancer.

Urine alkali agent useful for treatment of cancer patient

The present invention aims at providing novel means for administering Venetoclax, wherein the means reduces the burden on a patient caused by taking Venetoclax and achieves a good balance between the effect and safety of Venetoclax. The present invention relates to a water-soluble macromolecular derivative that includes a plurality of Venetoclaxs, each Venetoclax being linked to a terminal carboxyl group of a multi-arm water-soluble polymer via an amide bond.

Water-soluble macromolecular derivative of Venetoclax

The present invention relates to a pharmaceutical composition comprising a citrate salt for use in enhancing the effect of an anticancer drug.

Anticancer drug effect enhancer

An object of the present invention is to provide an oxaliplatin-encapsulating liposome aqueous dispersion that has excellent long-term storage stability. The present invention provides an aqueous dispersion of liposomes encapsulating oxaliplatin, the oxaliplatin-encapsulating liposome aqueous dispersion containing 2-morpholinoethanesulfonic acid in an external aqueous phase.

Stable oxaliplatin-encapsulating liposome aqueous dispersion and method for stabilizing same

An object of this invention is to provide a novel delivery means that enables efficient delivery of an active ingredient to a target cell. Such objective is attained by a lipoplex comprising dioleylphosphatidylethanolamine (DOPE), phosphatidylcholine, a cationic lipid, and an RNAi molecule and an industrial method for producing the same.

Method for producing lipoplex for topical administration and antitumor agent using such lipoplex

This invention provides a novel delivery means that enables efficient delivery of an active ingredient to a target cell. Such novel delivery means is a liposome for topical administration that consists of dioleylphosphatidylethanolamine (DOPE), phosphatidylcholine, and cationic lipid, that is not modified with PEG, and that is free of cholesterol.

Liposome for topical administration and application thereof

An object of the present invention is to further enhance the antitumor effect when oxaliplatin is administered in combination with a combination drug containing tegafur, gimeracil and oteracil potassium. According to the present invention, by using oxaliplatin encapsulated in a liposome preparation, combination therapy of oxaliplatin plus a combination drug containing tegafur, gimeracil and oteracil potassium, is revealed to show remarkably enhanced antitumor effect without increasing side effects.

Agent for enhancing anti-tumor effect comprising oxaliplatin liposome preparation, and anti-tumor agent comprising the liposome preparation

This method provides a method for delivering shRNA targeting TS in vivo. In addition, the following is provided: an antitumor agent, which comprises short hairpin RNA (shRNA) capable of inhibiting expression of thymidylate synthase by RNAi action and a PEG-modified cationic liposome, wherein the shRNA is bound to the surface of the PEG-modified cationic liposome and has an overhang comprising at least two nucleotides at the 3' end.

Growing community of inventors

Tokushima, Japan

Tatsuhiro Ishida